DURABLE Clinical Trial Results Show GlycoMark is Key Te...

DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing

DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing
Patients with Diabetes
Additional Studies Indicate GlycoMark May Be a More Effective Monitor Than
Hemoglobin A1C of Exenatide, Sitagliptin, Pramlintide and Prandial Insulin
Therapies in Certain Diabetic Populations

SAN FRANCISCO, June 7 /PRNewswire/ -- GlycoMark, Inc. announced today
results from the ongoing DURABLE clinical trial showing that the GlycoMark
blood test is a better reflection of glucose, particularly after-meal glucose
levels, than the gold standard hemoglobin A1C test in moderately controlled
patients with diabetes. These findings were reported by Kathleen Dungan, MD,
of Ohio State University (Columbus, OH) and investigators from Eli Lilly
(Indianapolis, IN) at the American Diabetes Association's 68th Annual
Scientific Sessions (ADA) in San Francisco.

This is the largest clinical study to evaluate the clinical utility of
GlycoMark to reflect after-meal glucose levels with 2,094 patients enrolled
from 11 countries. The DURABLE trial (Assessing the Durability of Basal vs.
Lispro Mix 75/25 Insulin Efficacy) confirms results from a smaller population
study completed by John Buse, MD (University of North Carolina), Steven
Wittlin, MD (University of Rochester), and Kathleen Dungan, MD, published in
the medical journal Diabetes Care in June 2006.

In the study, the 1,5-Anhydroglucitol blood test (GlycoMark) correlated
more strongly than hemoglobin A1C with all self-monitored plasma glucose
(SMPG) parameters, particularly after-meal glucose levels, in moderately
controlled patients with A1C levels less than 8.0%. Dr. Dungan concluded,
"The data support the use of 1,5-anhydroglucitol, in conjunction with A1C, in
moderately controlled patients with type 2 diabetes."

"This large clinical study validates the important role of the GlycoMark
test to effectively monitor patients with diabetes," said Eric Button,
President of GlycoMark, Inc. "Although patients may appear to be adequately
controlled by A1C results, it may not readily reveal elevated postprandial
spikes which are associated with dangerous cardiovascular complications.
GlycoMark can detect 'hidden' glucose spikes, allowing physicians to target
these spikes with specific treatments."

In a retrospective examination of studies (see below) evaluating the use
of GlycoMark to monitor exenatide, pramlintide, sitagliptin, and biphasic
insulin therapies, GlycoMark reflected changes in after-meal glucose levels
more dynamically than A1C in moderately controlled patients - underscoring the
ability of GlycoMark to detect underlying treatment effects on after-meal
glucose not revealed by A1C. The study, "The Use of 1,5-Anhydroglucitol
(GlycoMark) to Monitor New Classes of Therapies for Managing Post-meal Glucose
in Patients with Diabetes," was presented at the recent American Association
of Clinical Endocrinologists 2008 annual meeting in Orlando, Florida. Authors
of the study included Steven Wittlin (University of Rochester), Toshikazu
Yamanouchi (Teikyo University School of Medicine) and Antonio Ceriello
(Warwick Medical School).

Exenatide Improves Postprandial Glucose (PPG) Control in Patients With
Type 2 Diabetes as Measured by 1,5-Anhydroglucitol (GlycoMark)

Reference: Scientific Sessions of the American Diabetes Association - 2007
(David Kendall)

1,5-Anhydroglucitol (GlycoMark), a PPG Excursion Marker In
Pramlintide-Treated Subjects

Reference: American Association of Clinical Endocrinologists 2007 Annual
Meeting (Cameron Lush)

Efficacy and Safety of Sitagliptin Monotherapy in Japanese Patients with
Type 2 Diabetes

Reference: Diabetes Research and Clinical Practice 2008 (Kenji Noaka)
Does serum 1,5-AG establish a relationship between improvements in HbA1c
and postprandial glucose excursions? Supportive evidence utilizing the
differential effects between biphasic insulin aspart 30 and insulin glargine.

Reference: Diabetic Medicine 2008 (Alan Moses)
About GlycoMark

GlycoMark is an FDA approved test for monitoring intermediate glycemic
control by measuring the levels of a monosaccharide 1,5-anhydroglucitol (1,5-
AG) in blood. Multiple published studies in peer-reviewed journals have shown
that the 1,5-AG test is a specific index of postprandial hyperglycemia
(elevated after-meal glucose levels) and short-term glycemic control -
providing a useful complement to A1C testing. GlycoMark is being used in
clinical practices nationwide and is available at major reference laboratories
including Quest Diagnostics, LabCorp, Esoterix, Mayo Medical Laboratories,
ARUP Laboratories, and Specialty Laboratories. The test is also available at
most major contract research organizations for pharmaceutical research
studies.

GlycoMark was recently included in the International Diabetes Federation
(IDF) Global Diabetes Care Guidelines as an emerging tool to measure
after-meal glucose levels.

GlycoMark, Inc. is based in New York, New York and Winston-Salem, North
Carolina.

SOURCE GlycoMark, Inc.

Eric Button, President GlycoMark, Inc., +1-336-725-8190,
eric_button@glycomark.com